STAT+: Pharmalittle: We're reading about an FDA gender rule change, its program for one-day inspections, and more

The U.S. FDA proposed removing references to "gender" from its regulations, aiming to emphasize "biological sex," which could impact drug trials and representation of gender minorities in research. This change matters as it may alter how clinical trials are conducted and who participates, potentially affecting the inclusivity and validity of medical studies. Watch for reactions from legal experts and changes in industry practices regarding clinical trial demographics.

Read the full article at STAT Pharma

---

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.